2 weeks Ago By ABMN Staff
Maplelane Capital LLC acquired a new stake in shares of Crinetics Pharmaceuticals, Inc. ( NASDAQ:CRNX – Free Report ) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 160,000 shares of the company’s stock, valued at approximately $7,166,000.
Maplelane Capital LLC owned approximately 0.20% of Crinetics Pharmaceuticals at the end of the most recent reporting period. A number of other institutional investors also recently added to or reduced their stakes in the stock.
AQR Capital Management LLC grew its stake in shares of Crinetics Pharmaceuticals by 3.3% during the second quarter. AQR Capital Management LLC now owns 7,126 shares of the company’s stock worth $319,000 after acquiring an additional 227 shares during the last quarter.
Amalgamated Bank increased its stake in Crinetics Pharmaceuticals by 20.8% during the 2nd quarter. Amalgamated Bank now owns 2,692 shares of the company’s stock valued at $121,000 after purchasing an additional 464 shares in the last quarter.
Comerica Bank acquired a new position in Crinetics Pharmaceuticals during the 1st quarter valued at approximately $33,000. Hennion & Walsh Asset Management Inc. raised its holdings in shares of Crinetics Pharmaceuticals by 2.
5% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 38,087 shares of the company’s stock worth $1,783,000 after buying an additional 927 shares during the last quarter.
Finally, Quest Partners LLC acquired a new stake in shares of Crinetics Pharmaceuticals during the second quarter worth $42,000. Institutional investors own 98.51% of the company’s stock.
Analyst Ratings Changes Several research firms recently issued reports on CRNX. Oppenheimer reissued an “outperform” rating and issued a $73.00 target price (down from $74.
00) on shares of Crinetics Pharmaceuticals in a research report on Friday, August 9th. JMP Securities restated a “market outperform” rating and issued a $80.00 price objective on shares of Crinetics Pharmaceuticals in a research note on Tuesday, June 4th.
JPMorgan Chase & Co. upped their target price on Crinetics Pharmaceuticals from $47.00 to $54.
00 and gave the company an “overweight” rating in a research report on Tuesday, July 9th. Piper Sandler restated an “overweight” rating and set a $97.00 price objective on shares of Crinetics Pharmaceuticals in a research note on Tuesday, July 2nd.
Finally, HC Wainwright upped their price objective on shares of Crinetics Pharmaceuticals from $60.00 to $69.00 and gave the company a “buy” rating in a report on Friday, August 9th.
One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $68.55.
Insider Activity In related news, COO Jeff E. Knight sold 27,000 shares of the business’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $55.
00, for a total value of $1,485,000.00. Following the completion of the sale, the chief operating officer now owns 51,653 shares of the company’s stock, valued at approximately $2,840,915.
The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink . In other Crinetics Pharmaceuticals news, insider Stephen F. Betz sold 1,035 shares of the firm’s stock in a transaction on Tuesday, September 10th.
The stock was sold at an average price of $51.50, for a total value of $53,302.50.
Following the transaction, the insider now owns 68,576 shares in the company, valued at approximately $3,531,664. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website . Also, COO Jeff E.
Knight sold 27,000 shares of the company’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $55.00, for a total transaction of $1,485,000.
00. Following the sale, the chief operating officer now directly owns 51,653 shares of the company’s stock, valued at approximately $2,840,915. The disclosure for this sale can be found here .
Insiders sold 110,466 shares of company stock worth $5,711,756 over the last three months. 6.00% of the stock is currently owned by corporate insiders.
Crinetics Pharmaceuticals Stock Performance CRNX stock opened at $50.58 on Friday. The firm’s fifty day moving average is $52.
12 and its 200 day moving average is $48.19. The firm has a market cap of $4.
05 billion, a PE ratio of -13.38 and a beta of 0.63.
Crinetics Pharmaceuticals, Inc. has a one year low of $25.35 and a one year high of $55.
78. Crinetics Pharmaceuticals ( NASDAQ:CRNX – Get Free Report ) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.
94) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.08).
The company had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.47 million.
The firm’s quarterly revenue was down 59.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.
94) EPS. Research analysts predict that Crinetics Pharmaceuticals, Inc. will post -3.
72 earnings per share for the current fiscal year. About Crinetics Pharmaceuticals ( Free Report ) Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.
Recommended Stories Want to see what other hedge funds are holding CRNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crinetics Pharmaceuticals, Inc. ( NASDAQ:CRNX – Free Report ).
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
